Mumps disease and vaccination in Africa: A scoping review Authors: Irene Gobe, Thabiso Mogowa, Khutsafalo Kadimo, John Thato Tlhakanelo, Modisa Motswaledi Published: 2026 ABSTRACT ABSTRACTMumps, though often self-limiting, can cause serious complications such as meningitis, orchitis, infertility, deafness, and seizures. Despite rising cases in Africa, most countries do not vaccinate against mumps. This review compiled available evidence on mumps in Africa, focusing on morbidity, mortality, vaccine safety, transmission, and molecular characterization. A systematic search across major databases identified 22 relevant studies published between 1994 and 2024. Nearly half of the studies (45%; n = 10/22) were published in the most recent period (2018–2024), indicating increased research interest in recent years. Of the 22 included articles, 37% examined seroprevalence and incidence, 21% transmission and seroprevalence factors, 17% vaccine safety, 17% vaccination in HIV-positive individuals, and 8% molecular data. Reported seroprevalence ranged from 5 to 88.8% in children and exceeded 90% in adults. The MMR vaccine is generally safe but should be used cautiously in those immunocompromised or have allergic reactions to gelatin. Evidence of antibody loss after HAART in HIV-positive children supports re-vaccination. High seroprevalence without immunization suggests widespread natural infection. It is possible that mumps complications are underreported and under-investigated because of the presumed self-limiting nature of mumps infection. This underscores the need to include mumps vaccination in African immunization programs.KEYWORDS: Mumps review, Africa, vaccine Introduction Mumps is endemic worldwide. It is estimated that epidemics occur every 5 y especially in unvaccinated populations.1 Nonetheless, in many countries, especially those that are not vaccinating for it, mumps is not a notifiable disease. Therefore, there is limited surveillance data that can speak to incidence and complications of the infection except in cases of outbreaks.2 Although mumps infections are common in children aged between 5 and 9 y, adolescents and adults may be infected.3 The incubation period of mumps is 2–4 weeks after which nonspecific symptoms develop. These include headache, malaise, myalgia, and low-grade fever. These are followed by the typical symptoms which include unilateral or bilateral swelling of the parotid salivary glands.3 Mumps infections are generally self-limiting and without sequelae. However, complications may occur. Some of the complications that can occur with mumps include meningitis, encephalitis, orchitis (which is common among un-vaccinated pubertal and post-pubertal males), pancreatitis, nephritis, and myocarditis.4,5 Furthermore, albeit rare, long-term outcomes of mumps that can occur include deafness, seizures, cranial nerve palsies, and hydrocephalus.4 In regions where tuberculosis (TB) is endemic, mumps acute hydrocephalus has been shown to mimic TB meningitis and this can lead to unnecessary treatment with TB medication.6 Another possible long-term complication of mumps is sterility in men which may occur after orchitis. Mumps orchitis is associated with temporary reduced testosterone and reduced sperm production all of which may result in sub-infertility.7,8 Mumps infection is caused by a mumps virus, which belongs to the paramyxoviridae family. The virus is enveloped, negative sense, and non-segmented RNA virus.9 Humans are the only reservoirs of the virus.9 Mumps is an acute infection which commonly affects children and young adults. The infection is transmitted via respiratory droplets.3 While the mumps virus exists as a single serotype, there are 12 genotypes of the virus.2 Since mumps is usually a self-limiting infection, it is mostly neglected compared to other viral infections. However, cases of mumps have been rising in USA where vaccinations have long been introduced.10 Interestingly, in these developed vaccinating countries, mumps outbreaks are occurring in previously vaccinated young adults.5 The reason for this could be waning immunity, the efficacy of the vaccines, and/or changes in circulating mumps strains/genotypes.5 According to WHO data on reported mumps cases and incidence, mumps cases in the African region have fluctuated substantially in recent years: 94,491 cases were reported in 2020, followed by 100,576 cases in 2021. However, there was a marked increase to 231,965 cases in 2022 and 317,304 cases in 2023.11 Given that many countries do not consistently report mumps surveillance data to WHO, these figures are likely underestimates of the true burden. Despite the rising cases of mumps infections in Africa, most African countries are not vaccinating against mumps. The few African countries that have introduced the MMR vaccine in their immunization schedules include Egypt, Libya, and Algeria.12 The reasons why most African countries are not vaccinating are not clear. There is limited research output that aggregate available evidence to answer why African countries are not vaccinating against mumps. The aim of this study is to aggregate available empirical evidence on mumps disease in Africa. The review sheds light on issues pertaining to mumps disease such as morbidity and mortality rates, vaccine safety issues, transmission factors, and molecular characterization. Methodology This scoping review was conducted following the PRISMA Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA)13–15 and the PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation.16 Literature searching A predetermined search strategy was developed and translated for all the databases used to search databases including PubMed, Scopus, Web of Science, EBSCOHost (CINAHL), and Google Scholar on the 24th of September 2024 (Appendix A). Although a meta-search engine, Google Scholar was included in the literature searching. In addition,backward and forward snowballing were conducted. —this involved checking additional relevant studies in the reference sections of the included studies and the studies that cited the relevant studies.17 These steps were conducted to ensure that the searching is reasonably comprehensive. Overall, the literature searching yielded a total of 938 results which were subjected to the study inclusion/exclusion criteria. It should be noted that Google Scholar yielded 1,520 total results, but we screened only the first 100. This aligns with Cochrane standards and common practice, which recommend reviewing 100–300 initial results.18 Although screening more results would be ideal, Google Scholar was consulted solely to identify gray literature and supplemental studies missed by curated databases. Inclusion/exclusion criteria This scoping review included all the studies that reported on mumps disease and the use of mumps containing vaccine in routine immunization programme in Africa. Thus, all the studies that did not report on mumps and were not conducted in Africa as a setting were excluded. The three authors screened the first seven results together to develop rapport and two authors each screened all the remaining independently. The screening was completed in a meeting where the authors reconciled their independent selection and break the deadlocks. Data abstraction The data was extracted into a matrix or data extraction form with collective commons (columns) including author, title, year, country/region, purpose, methodology, article type, and key findings (Appendix B). The authors tested the matrix by abstracting five articles together and then abstracted separately. Once the data is captured into the matrix document, the entire matrix was reviewed for completeness (duplication, consistency, and accuracy). Data analysis The data was analyzed thematically, reading the matrix for familiarization with the data and using the language of the data to develop codes (data coding), grouping the codes into themes and sub-themes (categories and sub-categories). The relationships between codes, themes, and sub-themes were established by repeatedly comparing them to ensure consistency. Results Publication trends After data extraction, we had a total of 22 articles (Figure 1) which we analyzed for the review (Appendix B). Almost half of the articles were from South Africa, followed by Egypt with three articles. Democratic Republic of Congo (DRC), Somalia, Ghana, Sudan, and Tanzania recorded 1–2 papers each (Table 1). These are the only African countries captured on our search that have conducted research on the topic of mumps. Among these, no author name appears frequently. Each article retrieved had different authors. Retrieved articles span 1998–2024. Most articles were published in the years 2018–2024 (Figure 2). The oldest article was published in 1998 from South Africa. The newest articles were published in 2024 from Tanzania and South Africa. PRISMA flow diagram. Table 1.Trend analysis of mumps research in Africa by country.African countryNumber of articlesSouth Africa10Egypt3Zambia2Ghana2DRC2Somalia1Sudan1Tanzania1 Trend analysis of mumps research in Africa by country. Trend analysis of mumps research in Africa by year of publication. Article types Most data analyzed in this review was from research articles which accounted for 54% (n = 12/22) of the total article types used (Table 2). Surveys accounted for 18% (n = 4/22) of the total articles analyzed. There was one article each for the expert opinion, short report, and CME article types (Table 2). A few reviews were also included in this analysis (13%; n = 3/22). These reviews were not entirely on mumps disease; however, they covered some aspects of mumps disease and vaccination, e.g., a review on egg allergy and MMR vaccine and a review on immunization in patients with HIV (Table 1; Matrix table). Table 2.Trend analysis of mumps research in Africa by article type.Article typeNumber of articlesResearch article12Survey4Reviews3Short report1CME article1Expert opinion1CME: Continuing Medical Education. Trend analysis of mumps research in Africa by article type. CME: Continuing Medical Education. Research focus Five research themes have emerged in this review. These include prevalence/incidence, vaccine introduction and safety issues, immunization of HIV+ individuals, transmission risks, and mumps genotypes/genetic variations (Figure 3). In terms of study purpose, most articles focused on the seroprevalence and incidence of mumps infections (37%, n = 2/22), and the next predominant theme was transmission risk factors (21%, n = 5/22), vaccine safety (17%, n = 4/22), and vaccination of people living with HIV (17%, n = 4/22) followed by genotypes and molecular characterization (8%, n = 2/22) (Figure 3). Trend analysis of mumps research in Africa according to research themes. Seroprevalence/incidence of mumps Several studies have reported on the seroprevalence and incidence of mumps in Africa (Table 3). The incidence of mumps in Ghana was 41.2 per 100 000 during the period of 2010–2014.19 This incidence was higher than the one reported in Egypt where an incidence of 15.2 per 100 000 was reported in 2012 which further increased to 22.2 per 100 000 in 2013. The cases predominantly affected males and children aged <15 y.20 The relatively lower incidence reported in Egypt may be attributed to the introduction of the measles–mumps–rubella (MMR) vaccine into the national immunization programme in 1999,21 which likely contributed to reduced transmission and overall disease burden. Table 3.Seroprevalence of mumps IgG antibodies in different (unvaccinated) age groups.CountryAge groupMumps seroprevalence (%)SudanChildren (1–15 y)63.6Adult volunteers90.8Adult HCW97.1Egypt0–12 months79.5TanzaniaSchool age children(5–13 y)88.8DRC6–12 months5Children (>4 y)30HCW = Health Care Workers. Seroprevalence of mumps IgG antibodies in different (unvaccinated) age groups. HCW = Health Care Workers. In addition, four articles reported on the seroprevalence of mumps (Table 3). In a study conducted in DRC where children were assessed for serologic response, the prevalence of mumps antibodies increased with age: 5% among 6–12 months and 30% among children 4 y and older (P < .0001).22 In a cross sectional study that was conducted in Sudan, where dried blood spots were collected from children, adults, and health care workers (HCWs) to assess the seroprevalence of mumps in these groups, the seroprevalence of mumps antibodies among children was 63.6%, while it was 90.8% among adult volunteers and 97.1% among HCWs.23 The seropositivity of children for mumps antibodies was associated with the history of mumps (P = .003) and febrile rash (P = .014); the median titers for mumps antibodies in children, adults volunteers, and HCWs were 3562, 2655, and 3514RU/ml; and these titers were not significantly associated with age across the study groups. 23 In Egypt, the seropositivity rate for Mumps in unvaccinated infants was 79.5% between 2005 and 2006.24 In a study done among school-aged children in Tanzania, mumps IgG antibodies were detected in 88.8% (174/196, 95% CI: 83.5–92.5) of the participants.25 Mumps vaccine and safety issues One of the articles from this review addresses possible anaphylactic reaction to MMR vaccine in children with egg allergy.26 In this 2003 case report, a child was denied vaccination with MMR vaccine because the parents were afraid that the child would develop a reaction. Unfortunately, the child later developed measles and, subsequently, reactive arthritis. This report acknowledges the presence of egg in the MMR vaccine but provides evidence that the vaccine is safe in this group of children and further warns of the possible complications that can develop if these unvaccinated children were to develop mumps or measles. A CME article addresses the same issue by supporting the low risk associated with egg allergy and anaphylaxis following MMR vaccination.27 In addition, the report also highlights the presence of gelatin in some vaccines, including MMR that can cause anaphylaxis. Individuals with known allergy to gelatin may require evaluation by an allergist before administration and some may require graded dosing. In Egypt, a clinical trial was carried out to address the safety of an Indian-made MMR vaccine (TRESI-VAC®) containing Leningrad–Zagreb (L-Z) strain that was previously thought to have resulted in aseptic meningitis in Brazil, Bahamas, and India.28 This study was conducted in 453 119 children and revealed that in both younger (16–24 months) and older children (5–7 y), fever, local pain, and local redness were frequently experienced a few days following vaccination with some older children also developing more cases of parotitis than younger children. In addition, no cases of meningitis were recorded in this trial.28 Mumps immunization in HIV patients In a short report discussing vaccination on HIV-infected individuals, mumps containing vaccine is recommended for use in HIV-infected children who are not severely immunocompromised, i.e., those with CD4 cell (T-helper cells with cluster differentiation of 4) count of >200 ug/dl or >15%.29 The report further highlights that HIV-infected children tend to have lower post-vaccination antibody levels compared to HIV-uninfected peers. However, children receiving highly active antiretroviral therapy (HAART) demonstrated significantly improved antibody responses compared to untreated children (64% vs 21%), highlighting the role of immune reconstitution in vaccine responsiveness.29 These findings align with national vaccination guidelines developed in South Africa in 2018, which recommend MMR vaccination in HIV-positive children and adults with CD4 counts >200 cells/µL.30 Additional evidence from Eley31 reported that 38% of children who had detectable mumps antibodies prior to initiating HAART lost protective antibody levels within the first 6 months of therapy. However, re-immunization with the MMR vaccine resulted in seroconversion in 100% of these children, although antibody levels slightly declined to 94% after 24 weeks. This suggests that revaccination after immune reconstitution may be necessary to maintain protective immunity in HIV-infected children (Eley 2008). Overall, evidence from these articles supports the safety and immunogenicity of MMR vaccination in HIV-infected individuals with adequate immune status, while emphasizing the importance of immune monitoring and potential revaccination strategies following HAART initiation. Factors that affect mumps transmission and seroprevalence This review highlights several factors that contribute to mumps transmission and/or seroprevalence (Table 4). In a study investigating mumps outbreak in Zambia,34 the number of males and females infected were almost the same (49% and 51% cases, respectively). This study also shows that age group 1–9 y olds were mostly affected (71%) compared to the other age groups including adolescence and adults in which 6% and 11% of cases were recorded, respectively.34 Some of the risk factors associated with mumps infection in this Zambian outbreak included lack of immunity and close interpersonal contacts in schools.34 A serosurvey carried out in DRC showed that seropositivity was associated with increasing age, being female, number of children in the household, and living in an urban community.22 Contradictory results on the effect of sex were noted in this review: an Egyptian study noted that being male was a risk factor,20 while a study in Sudan shows that sex of children is not associated with seropositivity (p ≥ .05).23 Table 4.Factors associated with mumps seropositivity in unvaccinated populations reported across the included studies.FactorDirection of association with mumps seropositivityNo. of countriesReferenceSex↑seropositivity in female132 ↑seropositivity in males133 No association223,34Younger age↓seropositivity in those < 5 yrs123 ↑seropositivity in those > 5–15 yrs222,23Sharing utensils ↑seropositivity125Number of siblings ↑ seropositivity222,25Mother’s education and employment status↑seropositivity in children of mothers without tertiary education125 ↑seropositivity in children of mothers who are employed Gestational age and birth order ↑seropositivity in full term infants ↑seropositivity in 1st and 2nd order infants133Hypertensive status of the mother ↓seropositivity in infants born to hypertensive mothers133Being a health care worker ↑ seropositivity123History of febrile rash ↑seropositivity123Urban community ↑ seropositivity122↑increasing, ↓decreasing. Factors associated with mumps seropositivity in unvaccinated populations reported across the included studies. ↑seropositivity in female ↑seropositivity in female ↑seropositivity in males ↑seropositivity in males No association No association ↓seropositivity in those < 5 yrs ↓seropositivity in those < 5 yrs ↑seropositivity in those > 5–15 yrs ↑seropositivity in those > 5–15 yrs ↑seropositivity in children of mothers without tertiary education ↑seropositivity in children of mothers without tertiary education ↑seropositivity in children of mothers who are employed ↑seropositivity in children of mothers who are employed ↑increasing, ↓decreasing. Several other studies reviewed here reiterate the risk of mumps transmission: sharing utensils, increased number of siblings, mother’s education level, and employment status were other risk factors in a Tanzania study.25 Mumps IgG titers were found to be higher in Sudanese health care workers compared to other adult volunteers (p = .01).23 Additional factors associated with seropositivity highlighted in our review include birth order and gestational age. An Egyptian study showed that full term infants had higher maternal specific IgG antibodies when compared to their preterm counterparts.33 Furthermore, higher seropositivity was noted among infants of 1st and 2nd birth orders as compared to other higher birth orders.33 Mumps genotypes and genetic variations Phylogenetic analysis of Sudan mumps virus showed presence of the C-genotype among all tested samples.23 Sequence variants differing by 3–4 bases were also identified among the genotyped samples23 showing evidence of genetic evolution. Another study carried out in the Somali population found that several single nucleotide polymorphisms (SNPs) with regulatory or coding regions of cytokines and their receptors may be associated with antibody levels against several childhood infections including mumps.35 Discussion This review provides for the first time an overview of the available research that has been done in Africa regarding mumps infection. The review shows that there is minimal research on the topic of mumps in Africa. Out of the twenty-two (22) articles summarized, 10 are from South Africa. This is not surprising because South Africa is one of the largest economies in Africa according to Statista data36 which can facilitate research funding. Other countries from which publications on mumps were found include Egypt, Zambia, Ghana, and DRC. Prevalence or incidence was the most common theme in our review. Mumps seroprevalence was found to be as high as 97% among adults in Sudan23 indicating that even though most African countries have not included mumps in their vaccination schedule, the disease is common in the region. Our review shows that seroprevalence of mumps varies in the African region. Overall, reported mumps seroprevalence in African children shows marked variability between settings. In Tanzania, seroprevalence among children is high (88.8%),25 suggesting widespread exposure. In contrast, the DRC seroprevalence is much lower, with only 5% in infants and 30% in children, indicating greater susceptibility to outbreaks.22 In countries that are vaccinating against mumps, seroprevalence of mumps in children is very high, with USA at >90%37 and Thailand at 82%.38 Data from articles on the safety of mumps containing vaccine indicate that the vaccine is safe. Few concerns that have been raised include anaphylactic reaction to the vaccine in those that have gelatin allergy.26 The safety of mumps containing vaccine is reiterated by a large clinical trial in Egypt which showed that the MMR vaccine (TRESI-VAC) containing Leningrad–Zagreb (L-Z) strain was safe and only elicited minor adverse effects which included, fever, pain, redness, and some cases of parotitis especially in older children.28 These results are in agreement with other studies that have shown that MMR vaccines are generally well tolerated and are rarely associated with serious adverse events.39,40 An earlier clinical trial conducted in Brazil reported an increased incidence of aseptic meningitis following vaccination with a specific MMR formulation.41 However, this finding has not been consistently replicated in subsequent studies and was likely related to a particular vaccine strain or lot rather than representing an inherent safety concern of MMR vaccination. Such isolated events underscore the importance of robust pharmacovigilance systems to detect rare adverse events and ensure rapid investigation of potential vaccine-related signals. Beyond safety, impaired immunogenicity represents a key challenge in people living with HIV.30,40 HIV-associated immune dysregulation compromises the development and maintenance of immunological memory, resulting in reduced vaccine immunogenicity and waning antibody levels over time.42 Although antiretroviral therapy improves immune function, restoration of durable vaccine-induced immunity may be incomplete, particularly in children with vertically acquired infection. The documented waning or loss of protective antibodies following HAART initiation provides a biological rationale for considering revaccination strategies once adequate immune recovery has been achieved.31 Key factors associated with transmission and seroprevalence highlighted by this review include, among others, being young (1–9 y of age), waning immunity, crowding in schools, living in urban areas, sharing utensils, and being a health care worker. This is in agreement with other literature from the WHO and CDC which states that school-aged children and health care professionals are at greatest risks of mumps infections which indicates that crowded settings with frequent close contacts are major risks factors for mumps infection.3,43 This review also noted contradictory results on the relationship between gender and mumps infection or seroprevalence. While being female came out as a risk factor for acquiring mumps infection in the DRC study,22 on the contrary, being male was a risk factor in the Egyptian study.33 However, a study carried out in Sudan found no relationship between gender and mumps transmission risks.23 The effects of gender on acquisition and/or response to infections are complicated by other confounding factors which include, among others, occupational activities, sociocultural factors, and geographical distribution of pathogens44 all of which can increase exposure risk. There is truly little data on mumps circulating genotypes in Africa. This review only shows genotype C as discovered in one study from Sudan.23 Since this is the only study that determined mumps genotype in this review, this genotype cannot be generalized to the entire African region. In fact, according to data on GenBank, mumps genotype G seems to be the prevalent genotype globally at 91%, followed by genotype F at 3.9%, genotype H at 1.6%, and genotype C at 1.2%, while the other genotype (genotypes, I, J, K, N, A, B, D) is at less than 1%.2 Evidence of genetic evolution of the mumps virus is also shown in this review. Sequence variations have been noted in the Sudan study. Furthermore, a Somali study gives evidence that genetic variations in viral genomes, including the mumps virus, may affect antibody response levels.35 These results are not surprising, since recently, mumps outbreaks have been reported in previously vaccinated young adults.5 Apart from waning immunity in this group, the reasons for these outbreaks could be changes in circulating mumps strains/genotypes.5 The most widely used mumps containing vaccine uses the Jeryl Lynn (B level) strain for mumps which is a genotype A strain.45 This strain has been effective in producing neutralizing antibodies against all mumps genotypes even though antibodies to other strains were significantly lower than its own.46 Recent outbreaks in previously vaccinated individuals indicate that it might be time to switch the vaccine to the currently circulating genotype.5 Most information on mumps outbreaks in the African region was not captured in this study because the data is in newspapers and local websites. For example, there have been recent mumps outbreaks in Zimbabwe, Botswana, Lesotho, Zambia, and South Africa.47 This is one of the limitations of this review. Another limitation is insufficient peer reviewed articles. Future reviews on this topic should embrace all types of data on this topic not just published peer reviewed articles. This review demonstrates that research on mumps in the region remains limited. The relatively low reported mortality and morbidity may partly explain both the lack of scientific attention and the limited prioritization of mumps vaccination in many African countries. However, the widespread perception of mumps as a mild and self-limiting infection may also contribute to underreporting and under-investigation of its complications, reinforcing the view that vaccination is unnecessary. In addition, cost considerations may influence national immunization decisions. According to UNICEF vaccine pricing data, the measles only vaccine costs approximately 0.32 USD per dose, the measles–rubella (MR) vaccine 0.93 USD per dose, while the combined MMR vaccine costs 1.87 USD per dose.48 In resource-constrained settings, this higher price may discourage the inclusion of the mumps component in routine immunization programmes, particularly when the disease is perceived to pose a limited public health threat. Sub-Saharan Africa, however, continues to experience some of the highest rates of childhood mortality globally, largely driven by infectious diseases and malnutrition.49 In resource-constrained settings, preventing infections through vaccination is more cost-effective than managing complications. Given that there is no specific antiviral treatment for mumps, immunization remains the most effective strategy for preventing severe outcomes. Considering the potential for underrecognized complications and the broader public health context, African countries should consider the inclusion of mumps-containing vaccines in their national immunization schedules. Supplementary Material Appendix A_Search strategy.docx Appendix B_Data extraction tool.docx Biography Irene Gobe is a lecturer and researcher with specialisation in medical microbiology. Dr. Gobe is also a core member and chairperson of Botswana National Immunization Technical Advisory Group. Prof M. Motswaledi is an Associate Professor with specialization in haematology and Immunology. Dr J.T. Tlhakanelo is a public health physician with interests in communicable and non-communicable disease epidemiology and health economics, mainly health care financing and policy. Mr. Khutsafalo Kadimo is the medical librarian for the University of Botswana Faculty of Medicine with focus on systematic review service, Information literacy teaching (reference management software’s, database and effective web searching). Dr T. Mogowa is a resident medical doctor at the Faculty of Medicine, University of Botswana. Disclosure statement No potential conflict of interest was reported by the author(s). Supplemental material Supplemental data for this article can be accessed online at https://doi.org/10.1080/21645515.2026.2657111 References Associated Data Supplementary Materials Appendix A_Search strategy.docx Appendix B_Data extraction tool.docx